AstraZeneca boss: merger would create 'distraction'

AstraZeneca chief executive Pascal Soirot says a “merger of this magnitude would create a distraction” that could delay Astra’s projects and potentially life-saving drugs coming to market. Report by Fudgea. Like us on Facebook at http://www.facebook.com/itn and follow us on Twitter at http://twitter.com/itn